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Abstract
Introduction: Expanding the criteria for deceased organ donors increases the risk of delayed graft function (DGF)
and complicates kidney transplant outcome. We studied whether donor neutrophil gelatinase-associated lipocalin
(NGAL), a novel biomarker for acute kidney injury, could predict DGF after transplantation.
Methods: We included 99 consecutive, deceased donors and their 176 kidney recipients. For NGAL detection,
donor serum and urine samples were collected before the donor operation. The samples were analyzed using a
commercial enzyme-linked immunosorbent assay kit (serum) and the ARCHITECT method (urine).
Results: Mean donor serum NGAL (S-NGAL) concentration was 218 ng/mL (range 27 to 658, standard deviation
(SD) 145.1) and mean donor urine NGAL (U-NGAL) concentration was 18 ng/mL (range 0 to 177, SD 27.1). Donor S-
NGAL and U-NGAL concentrations correlated directly with donor plasma creatinine levels and indirectly with
estimated glomerular filtration rate (eGFR) calculated using the modification of diet in renal disease equation for
glomerular filtration rate. In transplantations with high (greater than the mean) donor U-NGAL concentrations,
prolonged DGF lasting longer than 14 days occurred more often than in transplantations with low (less than the
mean) U-NGAL concentration (23% vs. 11%, P = 0.028), and 1-year graft survival was worse (90.3% vs. 97.4%, P =
0.048). High U-NGAL concentration was also associated with significantly more histological changes in the donor
kidney biopsies than the low U-NGAL concentration. In a multivariate analysis, U-NGAL, expanded criteria donor
status and eGFR emerged as independent risk factors for prolonged DGF. U-NGAL concentration failed to predict
DGF on the basis of receiver operating characteristic curve analysis.
Conclusions: This first report on S-NGAL and U-NGAL levels in deceased donors shows that donor U-NGAL, but
not donor S-NGAL, measurements give added value when evaluating the suitability of a potential deceased kidney
donor.
Introduction
Deceased kidney donors are expected to have healthy
kidneys which will function well in the recipient after
transplantation. However, a considerable number of kid-
ney transplantations from deceased donors are compli-
cated by delayed graft function (DGF). There is no
consensus on the ultimate effect of short DGF, lasting
less than one week, on graft survival; however, when the
duration of allograft dysfunction becomes prolonged,
the negative effect on kidney graft survival becomes
evident [1,2]. The criteria for deceased donors have
been expanded because of organ shortages, and conse-
quently DGF has become more common [3,4]. At our
center, we have expanded our criteria for acceptable
kidney donors since 1995. During the past ten years, the
rate of DGF in transplantations from expanded criteria
donors (ECDs) has been 42%, compared to 23% in
transplantations from standard criteria donors (P =
0.001; unpublished data, Helsinki University Hospital,
Division of Transplantation, Kyllönen L and Salmela K).
The quality of donor kidneys has a clear impact on
long-term kidney allograft outcomes [5-7]. Various algo-
rithms have been designed for the evaluation of
deceased donors [8-10]. As these scoring systems also
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ischemia time and human leukocyte antigen (HLA)
matching, they cannot be used when deciding whether
to accept or reject the donor. In practice, the judgment
relies on the only readily available markers: diuresis and
plasma creatinine level.
Neutrophil gelatinase-associated lipocalin (NGAL) is a
new marker for acute kidney injury (AKI) which has
been studied after cardiac surgery, liver transplantation
and contrast media administration, as well as in inten-
sive care unit (ICU) patients( i nh e t e r o g e n e o u sp a t i e n t
groups and in patients with septic vs. nonseptic AKI), in
unselected patients who present to the emergency
department and in critically ill multiple trauma patients
[11-22]. So far, very little is known about NGAL after
kidney transplantation [23-26], and there are no pub-
lished data available on NGAL in deceased kidney
donors. We recently found that recipient urine NGAL
(U-NGAL) measured the first morning following trans-
plantation predicted DGF, particularly in cases where
early graft function (EGF) was expected on the basis of
diuresis and decreasing plasma creatinine concentration
[27]. In addition, recipient U-NGAL could predict DGF
lasting longer than two weeks [27].
Plasma creatinine level is known to be a poor early
detector of AKI. Thus, a simple laboratory test revealing
AKI early on would be useful for clinicians taking care
of potential donors in ICU when evaluating the quality
of their kidneys. In this prospective study, we wanted to
examine (1) the levels of serum NGAL (S-NGAL) and
U-NGAL in deceased kidney donors, (2) whether donor
S-NGAL and/or U-NGAL could be used as predictors
of DGF and especially (3) prolonged DGF after kidney
transplantation.
Materials and methods
Study design and patients
The present study was performed at Helsinki University
Hospital, which provides organ transplant service for
Finland, which has a population of 5.2 million. For this
study, we prospectively enrolled 99 consecutive,
deceased, heartbeating donors and their 176 adult kid-
ney recipients between August 2007 and December
2008. The study protocol was approved by the Helsinki
University Hospital Ethics Committee and the hospital’s
Department of Surgery. Written informed consent was
obtained from the recipients before enrollment.
Altogether 198 kidneys were obtained from the
99 donors. One kidney was not transplanted because of
a vascular lesion. Twenty-one kidneys were not included
in the study: six were used for pediatric recipients, two
were used for recipients who underwent combined kid-
ney and liver transplantation and one was used for a
combined kidney and lung transplantation. Nine kidneys
were shipped to the other Nordic countries according to
the Scandiatransplant exchange rules. Three patients did
not consent to participate in the study. The recipients of
the remaining 176 kidneys were included in this study.
Donor clinical history data were obtained from the
hospital records. The following variables were gathered:
age, gender, history of hypertension, need for cardiopul-
monary resuscitation, need for intracranial surgery, use
of vasopressor support, use of antidiuretic hormone
(ADH), plasma creatinine level, length of hospital stay
before brain death diagnosis, cause of death and multi-
organ or kidney-only donation. Estimated glomerular
filtration rate (eGFR) was calculated using the modifica-
tion of diet in renal disease equation for glomerular fil-
tration rate (MDRD equation) [28] in 96 adult donors.
In three donors who were under 18 years of age (ages 9,
16 and 17 years), eGFR was calculated using the
Schwartz formula [29]. ECDs were defined according to
the criteria described by Port et al. [7], which include all
donors older than 60 years of age, or donors older than
50 years of age with at least two of the following: plasma
creatinine concentration above 132 μmol/L (1.5 mg/dL),
cerebrovascular accident as the cause of death or a his-
tory of hypertension.
Intravenous steroids were given to all donors before
undergoing the organ retrieval operation, and they were
given mannitol before in situ perfusion was initiated.
The University of Wisconsin solution was used for in
situ perfusion and cold storage preservation of the kid-
neys. A biopsy for histological evaluation was taken
from the donor kidney before the initiation of in situ
perfusion. The biopsies were examined later and scored
using the Banff 97 criteria [30] and the Chronic Allo-
graft Damage Index (CADI) [31] to quantify renal
allograft histology. In both scoring systems, different
components in the biopsy are semiquantitatively evalu-
ated and then summarized. The CADI score may have a
value between 0 and 18, and it is obtained from indivi-
dual component scores (0 to 3) for glomerular sclerosis,
vascular intimal proliferation, interstitial inflammation,
mesangial matrix increase, tubular atrophy and intersti-
tial fibrosis.
Recipient clinical data were obtained from the
patients’ hospital records and the Finnish Kidney Trans-
plant Registry database. Plasma creatinine concentration
was recorded daily after transplantation during the reci-
pient’s stay in the transplant unit, then at 3 months and
1 year after transplantation. eGFR was calculated using
t h eM D R De q u a t i o n[ 2 8 ]a t3m o n t h sa n d1y e a ra f t e r
transplantation. Our standard immunosuppressive
regimen was used as previously described [27].
The primary recipient outcome variable was onset of
graft function after transplantation. DGF was defined
as described by Halloran et al. [32]: oliguria less than
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concentration greater than 500 μmol/L throughout the
first week after transplantation, or more than one dialy-
sis session needed during the first week after transplan-
tation. In the analyses examining DGF duration, we
divided the transplantations into three groups: EGF (n =
106), short DGF lasting less than 14 days (n = 43) and
prolonged DGF lasting 14 days or longer (n = 27).
NGAL sample collection and detection
Serum samples for NGAL analyses were taken for logis-
tical reasons in the donor hospital simultaneously with
blood samples for HLA determination. The serum sam-
ple was drawn before the diagnosis of brain death in 36
cases (mean 9.1 hours, range 0.5 to 24.5) and after that
in 63 cases (mean 1.4 hours, range 0.03 to 5.6). The
serum samples were taken before steroid administration
in 77 donors and after that in 22 donors. Urine samples
were taken by the transplant team at the beginning of
donor surgery. Thus all donors had already received the
steroids before their urine samples were taken. All sam-
ples were immediately centrifuged at 2,500 rpm at 4°C
for 10 minutes, and after that the serum and urine
supernatant were divided into tubes and frozen at -70°C.
No additives were used.
The S-NGAL assays were performed using a commer-
cial enzyme-linked immunosorbent assay (ELISA) kit
(BioPorto Diagnostics A/S, Gentofte, Denmark) as
recommended by the manufacturer. The measurements
were performed in duplicate and blinded to sample
sources and clinical outcomes. Serum samples were
available for NGAL analyses from 95 donors. In four
cases, S-NGAL levels could not be analyzed because of
inadequate (n =2 )o ri n c o r r e c t l yp r o c e s s e d( n =2 )
sampling.
The U-NGAL assays were performed using a standar-
dized clinical platform (ARCHITECT analyzer; Abbott
Diagnostics, Abbott Park, IL, USA) as previously
described [33]. Urine samples from 95 donors were
available for NGAL analyses. Donor U-NGAL levels
could not be determined in four cases because of inade-
quate (n = 1) or incorrectly processed (n = 3) sampling.
We divided the donors using the mean NGAL con-
c e n t r a t i o n sa sc u t o f f si n t oah i g hN G A Lg r o u p
(S-NGAL ≥214 ng/mL, n =3 8 ;U - N G A L≥18 ng/mL,
n = 26) and a low NGAL group (S-NGAL < 214 ng/mL,
n = 57; U-NGAL < 18 ng/mL, n = 69).
Statistical analyses
SPSS version 18.0 software (SPSS, Inc., Chicago, IL,
USA) was used for statistical analyses. All analyzed vari-
ables were tested for distribution. Student’s t-test and
analysis of variance were used to calculate samples with
normal distribution, and the Mann-Whitney U and
Kruskal-Wallis tests were used for analyses of samples
with skewed distribution. c
2 and Fisher’s exact tests
were employed for analyses of contingency tables. To
assess DGF predictors, multilogistic regression analyses
(forward and conditional) were used. Factors which
were significantly different between the DGF and EGF
groups in the univariate analyses, as well as for the
other clinically relevant factors in this respect, were
included in the multivariate analyses. The factors in the
multivariate analyses consisted of categorical variables
and the covariates of continuous variables. The para-
metric correlations were assessed using the Pearson cor-
relation coefficient, and the nonparametric correlations
were assessed using the Spearman correlation coeffi-
cient. Receiver operating characteristic curve (ROC)
analysis was performed to assess the potential of NGAL
to predict DGF. Positive and negative predictive values
were calculated using Bayes’ formula. A P value < 0.05
was considered significant.
Results
Table 1 shows the donor characteristics, and Table 2
shows the recipient characteristics and transplantation
details. After transplantation, DGF occurred in 70
(39.8%) of 176 cases. The mean time to onset of graft
function in the DGF transplantations was 12.0 days after








Cause of death, n (%)
Cerebrovascular accident 74 (74.7%)
Traumatic brain injury 25 (25.3%)
Mean plasma creatinine, μmol/L (± SD) 62 (± 19.4)
Mean eGFR, mL/min (± SD) 116 (± 34.8)
History of hypertension, n (%) 27 (27.3%)
Expanded criteria donors, n (%) 38 (38.4%)
Need for cardiopulmonary resuscitation, n (%) 21 (21.2%)
Need for antemortem intracranial surgery, n (%) 30 (30.3%)
Use of inotropes, n (%) 87 (87.9%)
Use of antidiuretic hormone, n (%) 60 (60.6%)
Multiorgan donors, n (%) 56 (56.6%)
Mean hospital days before brain death (± SD) 1.9 (± 2.1)
aeGFR, estimated glomerular filtration rate using the modification of diet in
renal disease (MDRD) equation for glomerular filtration rate in the 96 adult
donors and the Schwartz equation in three donors under 18 years of age.
Expanded criteria donors are defined as all donors who were (1) over 60 years
of age or (2) over 50 years of age and (3) had at least two of the following
clinical characteristics: hypertension, plasma creatinine level >132 μmol/L (1.5
mg/dL) or cerebrovascular accident as the cause of death [7]. SD, standard
deviation.
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DGF transplantations, 26 (37.1%) had prolonged DGF
lasting 14 days or longer. Graft survival at 1 year was
99.1% in the EGF group, 100% in the short DGF group
and 73.1% in the prolonged DGF group (P = 0.001).
Acute rejection occurred in 10 (5.7%) of 176 transplan-
tations at a mean of 16.8 days after transplantation
(range 7 to 49 days, SD 12.6).
Donor S-NGAL and U-NGAL
The mean donor S-NGAL concentration was 212 ng/mL
(range 27 to 720 ng/mL, SD 145.1). Donor S-NGAL
concentrations correlated directly with donor plasma
creatinine levels (R
2 =0 . 3 5 ,P = 0.001) and inversely
with donor eGFRs (R
2 = 0.24, P = 0.021).
The mean donor U-NGAL concentration was 18 ng/
mL (range 0 to 177, SD 26.1). Donor U-NGAL concen-
trations correlated directly with donor plasma creatinine
levels (R =0 . 3 7 ,P < 0.0001) and inversely with donor
eGFRs (R =0 . 2 4 ,P = 0.01). Donor U-NGAL concentra-
tions correlated directly with donor S-NGAL concentra-
tions (R = 0.40, P < 0.0001).
Donors treated with ADH had significantly lower mean
S-NGAL (188 ng/mL, SD 125.3) and U-NGAL (13 ng/
mL, SD 14.3) levels compared to those not treated with
ADH (S-NGAL: 249 ng/mL, SD 161.2, P = 0.002; U-
N G A L :2 6n g / m L ,S D3 6 . 6 ,P = 0.045). Donor S-NGAL
and U-NGAL levels did not correlate with donor age (R
= 0.15 and P = NS for S-NGAL and donor age; R = 0.12
and P = NS for U-NGAL and donor age) and were not
affected by gender, history of hypertension, use of vaso-
pressors, length of hospital stay, need for cardiopulmon-
ary resuscitation or intracranial surgery before brain
death, ECD or standard criteria donor status, and multi-
organ or kidney-only donation. In addition, there were
no significant differences between donor S-NGAL levels
in samples taken before or after brain death or before or
after steroid administration (see Additional file 1).
Using the high vs. low NGAL division, we found that
mean donor plasma creatinine level was significantly
higher and that mean eGFR was lower in the high NGAL
groups compared to the low NGAL groups (Table 3).
Donor biopsies
A representative biopsy for histological evaluation was
a v a i l a b l ef r o m9 7o f9 9d o n o r s .O ft h e9 7b i o p s i e s ,5 8
(58.6%) showed normal histology. The mean CADI score
of the biopsies was 0.72, ranging from 0 to 5 (Figure 1).
Overall, the changes in the kidney biopsies were rare,
apart from arterial changes (Table 4). Positive findings in
single Banff classification components were not associated
with the levels of donor plasma creatinine, eGFR, S-
NGAL or U-NGAL (data not shown). However, the
donors with high U-NGAL had significantly higher CADI
scores than the donors with low U-NGAL (Figure 1 and
Table 4).
Donor NGAL and DGF
Mean donor U-NGAL was significantly higher in cases
with prolonged DGF (35 ng/mL, SD 49.4) compared to
those with short DGF (15 ng/mL, SD 13.7) or EGF (15
ng/mL, SD 19.8) (P = 0.002). Mean donor S-NGAL did
not differ significantly between the prolonged DGF (220
ng/mL, SD 141.5), short DGF (234 ng/mL, SD134.6) and
EGF (206 ng/mL, SD 150.4) (P = NS) groups. There were
no significant differences in mean donor S-NGAL and U-
NGAL levels in the DGF (including both short and pro-
longed DGF) (S-NGAL 229 ng/mL, SD 136.4; U-NGAL
23 ng/mL, SD 33.3) and EGF (S-NGAL 206 ng/mL, SD
150.4, P = NS; U-NGAL 16 ng/mL, SD 19.8, P =0 . 0 5 8 )
groups. High donor U-NGAL level was associated with
more prolonged DGF and worse 1-year graft survival
compared to low donor U-NGAL level (Table 3).
DGF risk factors
Multivariate analysis was performed to assess the factors
predicting DGF and prolonged DGF. We included in
the multivariate analysis the factors differing signifi-
cantly between the DGF and EGF groups (donor age,
Table 2 Clinical characteristics of 176 kidney recipients
and their transplantation details
a
Clinical characteristics Statistics
Mean age, years (± SD) 56 (56.6%)
Females, n (%) 66 (37.5%)
Underlying kidney disease, n (%)
Polycystic disease 42 (23.8%)
Glomerulonephritis 35 (19.9%)
Diabetes mellitus 48 (27.3%)
Other 51 (30.0%)
Transplantation number, n (%)
First transplantation 161 (91.5%)
Retransplantation 15 (8.5%)
Mode of pretransplantation dialysis, n (%)
Hemodialysis 119 (67.6%)
Peritoneal dialysis 57 (32.4%)
Mean time of pretransplantation dialysis, days (± SD) 850 (588.8)
Mean plasma creatinine level, μmol/L (± SD)
3 months 124 (± 51.0)
1 year 116 (± 40.6)
Mean eGFR, mL/min (± SD)
3 months 55 (± 18.2)
1 year 58 (± 19.8)
1-year patient survival 98.9%
1-year graft survival 95.5%
Mean cold ischemia time, hours (± SD) 21.9 (± 3.70)
aeGFR was calculated using the MDRD equation.
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and recipient pretransplantation mode of and time on
dialysis) in addition to donor S-NGAL, U-NGAL, eGFR
and plasma creatinine levels.
None of the included factors appeared to be a signifi-
cant risk factor for DGF per se. Donor U-NGAL, ECD
status and eGFR emerged as independent risk factors for
prolonged DGF (Table 5). ROC analysis for donor U-
NGAL in predicting DGF (Figure 2) resulted in an area
under the curve (AUC) of 0.595 (95% confidence interval
(95% CI) 0.506 to 0.749). ROC analysis performed to pre-
dict prolonged DGF (Figure 3) resulted in an AUC of
0.616 (95% CI 0.493 to 0.739). Table 6 shows the sensitiv-
ities, specificities and positive and negative predictive
values at the lowest quartile (4 ng/mL), the median
(9 ng/mL), the mean (18 ng/mL) and the highest quartile
(20 ng/mL).
A pair kidney analysis was possible in 77 donors (154
kidneys). In 28 of 77 cases both donated kidneys had
EGF, in 13 of 77 cases both kidneys had DGF and in 36
of 77 cases one of the kidneys had DGF and the other
had EGF. If one kidney had DGF, the other was not at
increased risk for DGF (P = NS).
Discussion
In kidney transplantation, the donor issues have become
more important because, owing to a shortage of organs,
many donor kidneys which earlier would have been dis-
carded are now accepted for transplantation. DGF com-
plicates a significant amount of kidney transplantations
from deceased donors, and the rate of DGF is expected
to increase as more ECD kidneys are used [3,4]. It is
generally known that plasma creatinine is a poor marker
of AKI, especially when donor is in an unstable state,
and thus a test revealing the quality of donor kidneys
already at the time of donor evaluation would be extre-
mely welcome.
The gold standard for GFR determination is measure-
ment of insulin clearance. For practical reasons, it is
impossible to perform this test in a deceased donor. Esti-
mated GFR and plasma creatinine level are the only read-
ily available tools to assess donor kidney function. In
clinical practice, GFR is estimated by using different
equations, among which the MDRD equation [28] is the
most widely used. It is common knowledge that to obtain
reliable results, GFR should be calculated in a stable
situation. As the donors are not in a steady state, the
eGFRs and plasma creatinine concentrations must
be regarded only as approximate measures of kidney
function.
NGAL is a promising biomarker of AKI, and it has been
demonstrated to be useful in many clinical situations











Donors, n 38 57 26 69
Kidneys, n 69 99 52 116
Mean donor plasma creatinine, μmol/L (± SD) 70 (22.8) 57 (± 15.1) 0.021 71 (± 21.8) 59 (± 17.8) 0.006
Mean donor eGFR, mL/min (± SD) 108 (33.9) 124 (± 34.5) 0.033 105 (± 31.2) 122 (± 35.7) 0.039
Prolonged DGF (n = 25) 12 (17.4%) 13 (13.1%) 12 (23.1%) 13 (11.2%)
Short DGF (n = 41) 22 (31.9%) 19 (19.1%) 15 (28.8%) 26 (22.4%)
EGF (n = 102) 35 (50.7%) 67 (67.8%) NS 25 (48.1%) 77 (66.4%) 0.028
Mean recipient 1-year plasma creatinine level, μmol/L (± SD) 117 (43.8) 115 (± 37.7) NS 114 (± 28.5) 117 (± 45.0) NS
Mean Recipient 1-year eGFR mL/min (± SD) 57 (16.9) 60 (± 21.1) NS 57 (± 15.9) 59 (± 21.4) NS
1-year patient survival 98.6% 99.0% NS 96% 100% NS
1-year graft survival 91.4% 98.0% 0.050 90.3% 97.4% 0.048
aDGF, delayed graft function; EGF, early graft function; S-NGAL, serum neutrophil gelatinase-associated lipocalin; U-NGAL, urine neutrophil gelatinase-associated
lipocalin.
Figure 1 The distribution of Chronic Allograft Damage Index
(CADI) [31]scores of donor biopsies in the high (≥18 ng/mL)
and low (< 18 ng/mL) neutrophil gelatinase-associated
lipocalin (NGAL) groups. The highest CADI score in these biopsies
was 5. There were significantly more high CADI scores in the
high urine NGAL (U-NGAL) group than in the low U-NGAL group
(P = 0.010).
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NGAL concentrations have been shown to predict DGF
[23-27], but the literature on NGAL in kidney transplanta-
tion is limited. As far as we know, there are no previously
published data on NGAL in deceased organ donors. The
NGAL levels of our donors corresponded well to the levels
reported in several patient groups treated in ICUs
[17-20,34].
NGAL is an acute phase protein [35], and it is abun-
dant in human neutrophils and macrophages [36].
NGAL is induced by a range of cytokines [37-39]. Brain
death causes a large cytokine storm and inflammatory
response in the donor, and brain death, together with
other factors associated with donor death, might thus
explain the high levels of S-NGAL in our donors with
apparently healthy kidneys. None of our donors had
clinically verified AKI before death, and all appeared to
have good kidney function according to their plasma
creatinine levels and eGFRs. Furthermore, the findings
in donor biopsies taken before initiating in situ perfu-
sion were meager.
The S-NGAL and U-NGAL concentrations were ana-
lyzed using different methods. At the time the labora-
tory analyses were performed, only the ELISA and
ARCHITECT NGAL methods were commercially avail-
able. The ARCHITECT method is only available for
U-NGAL analysis. In clinical practice, the NGAL detec-
tion method has to be simple, easy to use, quick and
robust; hence the ELISA method is not optimal. Since
then, a point-of-care method of S-NGAL detection has
become available. Because of the use of different
Table 4 Donor kidney biopsy findings in the high and low NGAL groups
a
Serum NGAL Urine NGAL
Biopsy findings High, ≥214 ng/mL
(n = 38)
Low, < 214 ng/mL
(n = 57)
P value High, ≥18 ng/mL
(n = 26)
Low, < 18 ng/mL
(n = 69)
P value
Tubulitis 0 (0%) 0 (0%) NS 0 (0%) 0 (0%) NS
Intimal arteritis 0 (0%) 0 (0%) NS 0 (0%) 0 (0%) NS
Interstitial inflammation 1 (2.6%) 0 (0%) NS 1 (3.4%) 0 (0%) NS
Glomerulitis 0 (0%) 0 (0%) NS 0 (0%) 0 (0%) NS
Interstitial fibrosis 3 (7.9%) 2 (3.5%) NS 3 (10.3%) 2 (3.0%) NS
Tubular atrophy 3 (7.9%) 3 (5.3%) NS 3 (10.3%) 2 (3.0%) NS
Glomerulopathy 3 (7.9%) 3 (5.3%) NS 3 (10.3%) 2 (3.0%) NS
Mesangial matrix increase 1 (2.6%) 0 (0%) NS 1 (3.4%) 0 (0%) NS
Intimal thickening 11 (28.9%) 14 (24.6%) NS 9 (31.0) 15 (22.7%) NS
Arterial hyalinosis 8 (21.1%) 13 (22.8%) NS 8 (27.5%) 15 (22.7%) NS
CADI score, n
0 or 1 30 46 NS 17 61 0.010
≥28 1 1 9 8
aCADI, Chronic Allograft Damage Index [31]; NGAL, neutrophil gelatinase-associated lipocalin.
Table 5 Multivariate analysis of prolonged DGF
predictors
a
Clinical characteristics P value
Donor age, years 0.523
Donor urine NGAL, ng/mL 0.001
Donor serum NGAL, ng/mL 0.096
Donor plasma creatinine, μmol/L 0.152
Donor eGFR, mL/min 0.016
Expanded criteria donors 0.038
Cold ischemia time, hours 0.066
Mode of dialysis, hemodialysis or peritoneal dialysis 0.321
Time on dialysis before transplantation, days 0.460
aExpanded criteria donors were defined according to the criteria outlined by
Port et al. [7].
Figure 2 Receiver operating characteristic curve (ROC) analysis
of donor U-NGAL in predicting delayed graft function after
kidney transplantation.
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levels reported in this paper are not directly comparable.
The U-NGAL levels reported in this study were in
general low, corresponding to the levels of healthy indi-
viduals [40]. It has previously been suggested that
U-NGAL is likely to originate from the kidney [41].
Thus, high U-NGAL concentration in the donor is sug-
g e s t i v eo fl o c a ld a m a g ei nt h ek i d n e ya n ds e e m st ob e
more specific to AKI compared to S-NGAL, which also
may originate from other organs such as the lungs, bone
marrow and gastrointestinal tract [36]. It is thus likely
that the high S-NGAL levels detected in the donors did
not originate from the kidneys only, but from other sites
as well. Circulating NGAL is filtered through the glo-
merulus and reabsorbed in the proximal tubule, where it
is degraded. NGAL detected in the urine is believed to
derive mainly from tubular epithelial cells, where it is
synthesized de novo as a response to AKI [42,43]. How-
ever, some of the NGAL detected in the urine can also
b ed e r i v e df r o mo t h e ro r g a n s .S of a r ,i th a sn o tb e e n
possible to trace the origin of measured NGAL in the
urine in a clinical situation.
Diabetes insipidus is sometimes seen as a consequence
of brain death. Interestingly, we noticed significantly
lower U-NGAL levels in donors who had needed ADH
treatment because of massive postmortem polyuria.
ADH regulates urine volume and concentration and
may improve renal perfusion pressure. It does not result
in increased GFR. We can speculate that ADH treat-
ment causes a decrease in de novo tubular NGAL synth-
esis, but the mechanism behind that remains unclear.
We can also speculate that increased renal perfusion
pressure may result in better kidney function and less
damage and hence lower NGAL levels. On the other
hand, in addition to ADH treatment, diuretic use may
affect U-NGAL levels.
As expected, the pathological findings in the donor
biopsies were few, and thus it was not possible to
demonstrate a significant correlation between single
pathological changes in the biopsies and NGAL levels.
However, there were significantly higher CADI scores in
the high U-NGAL group compared to the low U-NGAL
group. This may indicate that kidneys with preexisting
chronic changes as shown by the CADI score are sus-
ceptible to injury during the brain death process. This
difference was not seen in the high vs. low S-NGAL
groups, again supporting the suggestion that U-NGAL
might be a better and more specific marker for AKI
than S-NGAL.
Mean donor S-NGAL and U-NGAL levels were rather
similar between the DGF and EGF groups. However,
high U-NGAL concentration in the donor was asso-
ciated with more DGF and, in addition, with a worse
outcome after transplantation, despite the fact that U-
NGAL levels in the majority of the donors remained
low. The etiology of DGF is multifactorial, and it is thus
possible that the effect of NGAL is concealed by other
factors associated with DGF, such as cold ischemia time,
donor age and ECD status. This also explains the result
of our pair analysis.
Prolonged DGF is a clinically relevant risk factor for
long-term kidney graft survival [1,2], as shown also in
this study. Donor U-NGAL was significantly higher in
Figure 3 ROC analysis of donor U-NGAL in predicting
prolonged, delayed graft function (longer than 14 days) after
transplantation.
Table 6 Sensitivity and specificity at different cutoff values in U-NGAL receiver operating characteristic curve analysis
predicting DGF and prolonged DGF
a
U-NGAL cutoff level, ng/mL DGF Prolonged DGF
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
4 77.3% 28.4% 0.42 0.65 82.6% 27.6% 0.16 0.91
9 60.6% 54.9% 0.47 0.68 47.8% 49.7% 0.14 0.85
18 37.9% 77.5% 0.53 0.65 47.8% 74.5% 0.24 0.90
20 34.8% 79.4% 0.53 0.65 43.5% 76.6% 0.24 0.89
aNPV, negative predictive value; PPV, positive predictive value. The selected cutoff values are the lowest quartile (4 ng/mL), the median (9 ng/mL), the mean (18
ng/mL) and the highest quartile (20 ng/mL).
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with early function or only short DGF, and donor U-
NGAL was also an independent risk factor for pro-
longed DGF in the multivariate analysis. However, U-
NGAL failed to show predictive power in the ROC ana-
lysis. Donor U-NGAL level seems to reflect the quality
of the donor kidney; kidneys from donors with higher
U-NGAL levels were more susceptible to ischemia-
reperfusion injuries and had less reserve capacity to
tolerate stress.
Our study has certain limitations. We did not examine
other relevant biomarkers in parallel, which would have
been valuable in the evaluation of the NGAL results.
The possible confounding effects of donor treatment on
NGAL concentration and NGAL analyses are not
known and thus could not be eliminated. Our study also
has strengths. It is the first prospective study to examine
S-NGAL and U-NGAL levels in deceased kidney donors.
This study comprised consecutive deceased donors and
represents well our general deceased donor population.
Conclusions
This is the first report on S-NGAL and U-NGAL levels
in deceased kidney donors. Kidneys from donors with
high U-NGAL values had significantly more prolonged
DGF and more histological findings (higher CADI
scores) in donor biopsies, but the predictive power of
U-NGAL with regard to the onset of graft function was
weak. Donor S-NGAL levels did not have predictive
power with regard to the onset of graft function after
transplantation. Donor U-NGAL level, but not S-NGAL
level, is useful when evaluating a potential deceased
organ donor.
Key messages
￿ Deceased donor U-NGAL concentration is useful
when evaluating the kidneys of potential organ
donor candidates in the ICU.
￿ The mean S-NGAL concentration (determined by
ELISA) in deceased donors was 212 ng/mL, corre-
sponding to the previously reported levels in criti-
cally ill patients.
￿ The mean U-NGAL concentration (determined by
the ARCHITECT method) was 18 ng/mL, which was
well within the range of healthy controls.
￿ Deceased donor U-NGAL concentration is more
specific than S-NGAL concentration to kidney
injury.
￿ High deceased donor U-NGAL concentration was
associated with prolonged oliguria after kidney trans-
plantation and chronic histological changes in donor
kidney biopsies, but it was a poor predictor of DGF
in individual cases.
Additional material
Additional file 1: Donor serum and urine neutrophil gelatinase-
associated lipocalin (U-NGAL) and donor parameters. The additional
data file shows the association between donor parameters and serum
NGAL and U-NGAL concentrations.
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